Coactivators Regulating EBV Lytic Transcription
调节 EBV 裂解转录的共激活剂
基本信息
- 批准号:6754546
- 负责人:
- 金额:$ 26.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-06-01 至 2006-05-31
- 项目状态:已结题
- 来源:
- 关键词:DNA footprintingEpstein Barr virusHerpesviridae diseaseacyltransferasechromatinenzyme activitygene induction /repressiongenetic promoter elementhost organism interactionimmunoprecipitationmicroorganism culturenucleosomesregulatory genetranscription factorviral carcinogenesisvirus geneticsvirus infection mechanismvirus protein
项目摘要
DESCRIPTION (provided by applicant): Regulation of EBV lytic cycle gene
expression may have important and underappreciated clinical significance for
EBV-related malignancies and diseases. EBV establishes a latent infection in
B-lymphocytes that can be disrupted by transcriptional activation of the viral
immediate early genes BZLF1 (Zta) and BRLF1 (Rta). The EBV genome exists as a
nucleosomal episome during latency, and histone deacetylase inhibitors are
potent stimulators of viral lytic gene expression. Reactivation correlates with
histone hyperacetylation at the Zta and Rta promoters, further indicating the
importance of chromatin modification in controlling the switch from latent to
lytic transcription. In this application, we propose to test the hypothesis
that EBV reactivation is regulated by chromatin modifications. Our preliminary
data suggests that the Zta promoter is actively repressed by a histone
deacetylase (HDAC)-associated corepressor that can be relieved by CBP/p300
histone acetylase (HAT) activity. Specific aim 1 will investigate the
regulation of the Zta promoter by chromatin modification and remodeling. We
have also found that CBP potentiates Zta transcription activation in a complex
and promoter-dependent manner. Specific aim 2 will investigate the mechanisms
of CBP transcriptional coactivation of Zta. Finally, we have found that Zta
stimulates the nucleosome-specific HAT activity of CBP by a mechanism that we
believe is novel and highly significant. Specific aim 3 explores the
biochemical basis and biological significance of Zta mediated stimulation of
CBP HAT activity. These aims should provide information important for EBV
regulation of lytic cycle gene expression, in particular, and for eukaryotic
transcription regulation, in general.
描述(由申请人提供):EBV裂解周期基因的调节
表达可能具有重要且低估的临床意义
与EBV相关的恶性肿瘤和疾病。 EBV在
B淋巴细胞可能会因病毒的转录激活而破坏
直接的早期基因BZLF1(ZTA)和BRLF1(RTA)。 EBV基因组作为一个
潜伏期和组蛋白脱乙酰基酶抑制剂期间的核小体偶发组是
病毒裂解基因表达的有效刺激剂。重新激活与
ZTA和RTA启动子的组蛋白高乙酰化,进一步表明
染色质修饰在控制从潜在到的开关中的重要性
裂解转录。在此应用中,我们建议检验假设
EBV重新激活受染色质修饰调节。我们的初步
数据表明ZTA启动子被组蛋白积极抑制
脱乙酰基酶(HDAC)相关的Corepressor可以通过CBP/P300缓解
组蛋白乙酰酶(HAT)活性。特定目标1将调查
通过染色质修饰和重塑对ZTA启动子进行调节。我们
还发现CBP在复合物中增强了ZTA转录激活
和促进者依赖性方式。特定目标2将研究机制
ZTA的CBP转录共激活。最后,我们发现ZTA
通过我们的机制刺激CBP的核小体特异性HAT活性
相信是新颖的,而且非常重要。特定目标3探索
ZTA介导的刺激的生化基础和生物学意义
CBP帽子活动。这些目标应为EBV提供重要的信息
尤其是裂解周期基因表达的调节,对于真核生物
通常,转录调节。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL M LIEBERMAN其他文献
PAUL M LIEBERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL M LIEBERMAN', 18)}}的其他基金
Project 4: Regulation of EBV Latency and Oncogenesis by Hypoxia
项目4:缺氧对EBV潜伏期和肿瘤发生的调节
- 批准号:
10714176 - 财政年份:2023
- 资助金额:
$ 26.54万 - 项目类别:
Epigenomic Drivers of EBV Epithelial Cancers
EB 病毒上皮癌的表观基因组驱动因素
- 批准号:
10627690 - 财政年份:2023
- 资助金额:
$ 26.54万 - 项目类别:
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial Cancers
针对 EB 病毒上皮癌的表观遗传和代谢控制
- 批准号:
10627689 - 财政年份:2023
- 资助金额:
$ 26.54万 - 项目类别:
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL
EBNA1 抑制剂用于治疗 EBV 阳性 DLBCL
- 批准号:
10719866 - 财政年份:2023
- 资助金额:
$ 26.54万 - 项目类别:
Drugging EBNA1 to Treat EBV-Associated Cancers - Diversity Supplement
使用 EBNA1 药物治疗 EBV 相关癌症 - Diversity Supplement
- 批准号:
10818976 - 财政年份:2021
- 资助金额:
$ 26.54万 - 项目类别:
Drugging EBNA1 to Treat EBV-Associated Cancers
药物 EBNA1 治疗 EBV 相关癌症
- 批准号:
10185459 - 财政年份:2021
- 资助金额:
$ 26.54万 - 项目类别:
Regulation of EBV Latency by Purine Metabolism and Signaling
通过嘌呤代谢和信号传导调节 EBV 潜伏期
- 批准号:
10298045 - 财政年份:2021
- 资助金额:
$ 26.54万 - 项目类别:
相似海外基金
Transcription and Replication of Oncogenic Viruses in Hypoxia
缺氧条件下致癌病毒的转录和复制
- 批准号:
10714172 - 财政年份:2023
- 资助金额:
$ 26.54万 - 项目类别:
Epstein Barr Virus Driven Mechanisms of Post Transplant Lymphoproliferative Disease
EB 病毒驱动的移植后淋巴增殖性疾病的机制
- 批准号:
10755055 - 财政年份:2023
- 资助金额:
$ 26.54万 - 项目类别:
"Project 3" Defining the in vivo function of ncRNAs during MHV68 latency and lymphomagenesis
“项目 3”定义 ncRNA 在 MHV68 潜伏期和淋巴瘤发生过程中的体内功能
- 批准号:
10865790 - 财政年份:2023
- 资助金额:
$ 26.54万 - 项目类别:
Defining host mechanisms that restrict EBV lytic reactivation
定义限制 EBV 裂解再激活的宿主机制
- 批准号:
10748051 - 财政年份:2023
- 资助金额:
$ 26.54万 - 项目类别:
Tiny RNAs as new potential biomarkers for gammaherpesvirus-driven neurological and central nervous system diseases
微小RNA作为伽马疱疹病毒驱动的神经和中枢神经系统疾病的新潜在生物标志物
- 批准号:
10727761 - 财政年份:2023
- 资助金额:
$ 26.54万 - 项目类别: